Weekly gemcitabine in advanced or metastatic solid tumors - A clinical phase I study

Camillo F. Pollera, Anna Ceribelli, Marcello Creccon, Federico Calabresi

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Gemcitabine (GEM) is a novel deoxycytidine analogue which has shown promising antitumor activity in solid tumor models and a broad range of schedule-dependent MTDs (12-4560 mg/m2) in preliminary clinical studies. The present phase I trial evaluated escalating doses of weekly GEM using a 30-min infusion at a starting dose-level of 300 mg/m2/wk x 3 every 28 days. At least 3 patients entered each dose-level step and 3 more cases were treated when significant toxicity was seen. A total of 39 patients with various advanced solid tumors and prior chemotherapy entered this study. Six escalation steps (102 courses) were tested to define the MTD at 1,370 mg/m2/wk. No definite dose-effect relationships were observed for myelosuppression up to 1,095 mg/m2/wk. However, increased severity of leucopenia (dose-limiting) and greater non-hematologic toxicity as well as a higher number of toxic treatment delays, requiring subsequent dose attenuation in 6 out of 12 patients, were observed at 1,370 mg/ m2/wk. In all, 6 out of 11 patients experiencing WHO grade≥ 3 toxicity (11/21 events recorded in 11/18 courses) were treated at the MTD. Clinically significant toxicity included (patients with WHO grade 2-3): leucopenia (44%), thrombocytopenia (26%), anemia (23%), fever (69%), emesis (38%) and AST/ALT rise (26%). Mild proteinuria, ankle edema, skin rash, hair loss and mucositis were seen in ≤ 5%. The good tolerability and the evidence of antitumor activity of GEM at doses ≥ 875 mg/m2/wk (1 CR and 3 PRs in 15 bladder cancer patients) encourage further phase II studies at much higher dose-levels (1,370 mg/m2) than previously suggested.

Original languageEnglish
Pages (from-to)111-119
Number of pages9
JournalInvestigational New Drugs
Volume12
Issue number2
DOIs
Publication statusPublished - Jun 1994

Fingerprint

gemcitabine
Neoplasms
Leukopenia
Deoxycytidine
Mucositis
Poisons
Alopecia
Exanthema
Proteinuria
Urinary Bladder Neoplasms
Ankle
Thrombocytopenia
Vomiting
Anemia
Edema
Appointments and Schedules
Fever
Drug Therapy

Keywords

  • gemcitabine
  • phase I study
  • solid tumors

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Weekly gemcitabine in advanced or metastatic solid tumors - A clinical phase I study. / Pollera, Camillo F.; Ceribelli, Anna; Creccon, Marcello; Calabresi, Federico.

In: Investigational New Drugs, Vol. 12, No. 2, 06.1994, p. 111-119.

Research output: Contribution to journalArticle

Pollera, Camillo F. ; Ceribelli, Anna ; Creccon, Marcello ; Calabresi, Federico. / Weekly gemcitabine in advanced or metastatic solid tumors - A clinical phase I study. In: Investigational New Drugs. 1994 ; Vol. 12, No. 2. pp. 111-119.
@article{2d26256eb314402181ac39f215821fc4,
title = "Weekly gemcitabine in advanced or metastatic solid tumors - A clinical phase I study",
abstract = "Gemcitabine (GEM) is a novel deoxycytidine analogue which has shown promising antitumor activity in solid tumor models and a broad range of schedule-dependent MTDs (12-4560 mg/m2) in preliminary clinical studies. The present phase I trial evaluated escalating doses of weekly GEM using a 30-min infusion at a starting dose-level of 300 mg/m2/wk x 3 every 28 days. At least 3 patients entered each dose-level step and 3 more cases were treated when significant toxicity was seen. A total of 39 patients with various advanced solid tumors and prior chemotherapy entered this study. Six escalation steps (102 courses) were tested to define the MTD at 1,370 mg/m2/wk. No definite dose-effect relationships were observed for myelosuppression up to 1,095 mg/m2/wk. However, increased severity of leucopenia (dose-limiting) and greater non-hematologic toxicity as well as a higher number of toxic treatment delays, requiring subsequent dose attenuation in 6 out of 12 patients, were observed at 1,370 mg/ m2/wk. In all, 6 out of 11 patients experiencing WHO grade≥ 3 toxicity (11/21 events recorded in 11/18 courses) were treated at the MTD. Clinically significant toxicity included (patients with WHO grade 2-3): leucopenia (44{\%}), thrombocytopenia (26{\%}), anemia (23{\%}), fever (69{\%}), emesis (38{\%}) and AST/ALT rise (26{\%}). Mild proteinuria, ankle edema, skin rash, hair loss and mucositis were seen in ≤ 5{\%}. The good tolerability and the evidence of antitumor activity of GEM at doses ≥ 875 mg/m2/wk (1 CR and 3 PRs in 15 bladder cancer patients) encourage further phase II studies at much higher dose-levels (1,370 mg/m2) than previously suggested.",
keywords = "gemcitabine, phase I study, solid tumors",
author = "Pollera, {Camillo F.} and Anna Ceribelli and Marcello Creccon and Federico Calabresi",
year = "1994",
month = "6",
doi = "10.1007/BF00874440",
language = "English",
volume = "12",
pages = "111--119",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Weekly gemcitabine in advanced or metastatic solid tumors - A clinical phase I study

AU - Pollera, Camillo F.

AU - Ceribelli, Anna

AU - Creccon, Marcello

AU - Calabresi, Federico

PY - 1994/6

Y1 - 1994/6

N2 - Gemcitabine (GEM) is a novel deoxycytidine analogue which has shown promising antitumor activity in solid tumor models and a broad range of schedule-dependent MTDs (12-4560 mg/m2) in preliminary clinical studies. The present phase I trial evaluated escalating doses of weekly GEM using a 30-min infusion at a starting dose-level of 300 mg/m2/wk x 3 every 28 days. At least 3 patients entered each dose-level step and 3 more cases were treated when significant toxicity was seen. A total of 39 patients with various advanced solid tumors and prior chemotherapy entered this study. Six escalation steps (102 courses) were tested to define the MTD at 1,370 mg/m2/wk. No definite dose-effect relationships were observed for myelosuppression up to 1,095 mg/m2/wk. However, increased severity of leucopenia (dose-limiting) and greater non-hematologic toxicity as well as a higher number of toxic treatment delays, requiring subsequent dose attenuation in 6 out of 12 patients, were observed at 1,370 mg/ m2/wk. In all, 6 out of 11 patients experiencing WHO grade≥ 3 toxicity (11/21 events recorded in 11/18 courses) were treated at the MTD. Clinically significant toxicity included (patients with WHO grade 2-3): leucopenia (44%), thrombocytopenia (26%), anemia (23%), fever (69%), emesis (38%) and AST/ALT rise (26%). Mild proteinuria, ankle edema, skin rash, hair loss and mucositis were seen in ≤ 5%. The good tolerability and the evidence of antitumor activity of GEM at doses ≥ 875 mg/m2/wk (1 CR and 3 PRs in 15 bladder cancer patients) encourage further phase II studies at much higher dose-levels (1,370 mg/m2) than previously suggested.

AB - Gemcitabine (GEM) is a novel deoxycytidine analogue which has shown promising antitumor activity in solid tumor models and a broad range of schedule-dependent MTDs (12-4560 mg/m2) in preliminary clinical studies. The present phase I trial evaluated escalating doses of weekly GEM using a 30-min infusion at a starting dose-level of 300 mg/m2/wk x 3 every 28 days. At least 3 patients entered each dose-level step and 3 more cases were treated when significant toxicity was seen. A total of 39 patients with various advanced solid tumors and prior chemotherapy entered this study. Six escalation steps (102 courses) were tested to define the MTD at 1,370 mg/m2/wk. No definite dose-effect relationships were observed for myelosuppression up to 1,095 mg/m2/wk. However, increased severity of leucopenia (dose-limiting) and greater non-hematologic toxicity as well as a higher number of toxic treatment delays, requiring subsequent dose attenuation in 6 out of 12 patients, were observed at 1,370 mg/ m2/wk. In all, 6 out of 11 patients experiencing WHO grade≥ 3 toxicity (11/21 events recorded in 11/18 courses) were treated at the MTD. Clinically significant toxicity included (patients with WHO grade 2-3): leucopenia (44%), thrombocytopenia (26%), anemia (23%), fever (69%), emesis (38%) and AST/ALT rise (26%). Mild proteinuria, ankle edema, skin rash, hair loss and mucositis were seen in ≤ 5%. The good tolerability and the evidence of antitumor activity of GEM at doses ≥ 875 mg/m2/wk (1 CR and 3 PRs in 15 bladder cancer patients) encourage further phase II studies at much higher dose-levels (1,370 mg/m2) than previously suggested.

KW - gemcitabine

KW - phase I study

KW - solid tumors

UR - http://www.scopus.com/inward/record.url?scp=0027946936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027946936&partnerID=8YFLogxK

U2 - 10.1007/BF00874440

DO - 10.1007/BF00874440

M3 - Article

C2 - 7860227

AN - SCOPUS:0027946936

VL - 12

SP - 111

EP - 119

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -